-
Oppenheimer Discusses Phase III Results From Gilead
Tuesday, July 12, 2011 - 9:20am | 175Oppenheimer & Co. is out with a research report on Gilead (NASDAQ: GILD), as the company released ph.III results for GILD's QUAD pill. It has an Outperform rating and a $45 price target. In a note to clients, Oppenheimer writes, "With ph.III results for GILD's QUAD pill vs. Truvada/Reyataz (...
-
Piper Jaffray Reiterates Overweight and PT of $63 on Vertex Pharmaceuticals
Tuesday, July 12, 2011 - 9:06am | 43Piper Jaffray reiterated its Overweight rating on Vertex Pharmaceuticals (NASDAQ: VRTX). At the same time, the rating agency left its price target on the company's stock unchanged at $63. On Monday, VRTX ended the day at $50.27.
-
Exact Sciences Initiates Enrollment of Large Prospective CRC Screening Trial
Tuesday, July 12, 2011 - 8:15am | 252Exact Sciences (Nasdaq: EXAS) today announced the initiation of the pivotal trial for the company's multi-marker molecular diagnostic screening test for the early detection of colorectal cancer. The multi-center DeeP-C study (Multi-Target Colorectal Cancer Screening Test for the Detection of...
-
Arena Says APD811 Showed Proportionate Pharmacokinetic Exposure
Tuesday, July 12, 2011 - 8:11am | 105Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH. The randomized, double-blind and placebo-...
-
Celsion Appoints Gregory Weaver as CFO
Tuesday, July 12, 2011 - 8:09am | 98Celsion Corporation (NASDAQ: CLSN) today announced the appointment of Gregory Weaver, a Director of Celsion Corporation since 2005, to the role of Senior Vice President and Chief Financial Officer, and the promotion of Jeffery Church, currently Vice President and Chief Financial Officer, to the...
-
Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Tuesday, July 12, 2011 - 8:01am | 266Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH. The randomized, double-blind and placebo-...
-
A Peek Into The Market Before The Trading Starts
Tuesday, July 12, 2011 - 7:58am | 407Pre-open movers US stock futures are lower this morning, as debt fears moved to Italy. Futures on the Dow Jones Industrial Average dropped 96 points to 12,393.00 and futures on the S&P 500 stock index fell 14.20 points to 2,344.75. Nasdaq 100 futures declined 22.25 points to 2,344.75. A Peek...
-
Deutsche Bank Reiterates Buy on Alexion Pharmaceuticals
Tuesday, July 12, 2011 - 7:54am | 45Deutsche Bank reiterated its Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN). At the moment, DB has a price target of $53 placed on the company's stock. On Monday, ALXN added 0.14% to its value to end the day at $50.37.
-
IsoRay Announces World's First Cesium-131 Treatment for Lung Cancer Using da Vinci Robotic Surgery System
Tuesday, July 12, 2011 - 7:32am | 359IsoRay, Inc. (NYSE: ISR) announced another milestone, today, in the use of its proprietary Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) in mesh. Dr. Deepak Khuntia, known as one of the nation's leading thought leaders in lung and brain tumors, performed the world's first...
-
Aeterna Zentaris Granted Patent for Perifosine by European Patent Office
Tuesday, July 12, 2011 - 7:31am | 102Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced that the European Patent Office has granted a patent for the use of alkyl phosphocholines, more specifically perifosine (octadecyl 1,1-dimethylpiperidino-4-yl phosphate), in the preparation of a medicament for the treatment of benign and...
-
PharmAthene's rPA Anthrax Vaccine Program Demonstrates 36 Month Product Stability
Tuesday, July 12, 2011 - 7:03am | 157PharmAthene, Inc. (NYSE: PIP) announced today that it has achieved an important program milestone in its recombinant protective antigen anthrax vaccine program and demonstrated 36 month stability of its rPA drug product candidate previously produced at Avecia Biologics Laboratories in the United...
-
Twelve ETFs Trading Near 52-Week Highs
Tuesday, July 12, 2011 - 6:56am | 874First Trust Consumer Staples AlphaDEX (NYSE: FXG) is up more than 20% year to date. The investment seeks results that correspond generally to the price and yield of an equity index called the StrataQuant Consumer Staples Index. Top holdings include Green Mountain Coffee Roasters (NASDAQ: GMCR),...
-
Stocks to Watch for Tuesday 07/12/11: Fresh 52 Week Highs and Lows
Monday, July 11, 2011 - 5:09pm | 1546Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels. The following stocks hit new 52-week highs in Monday's trading session (listed from highest total volume to lowest): 1) BioSante Pharmaceuticals (NASDAQ: BPAX...
-
Pluristem Therapeutics Eyeing Daily Highs
Monday, July 11, 2011 - 2:49pm | 132Shares of Pluristem Therapeutics (NASDAQ: PSTI) are trading higher on the session by 8.71%, at $3.62. The stock has been garnering bull support as of late and broke out of a key long-term range this morning, touching a high of $3.66. While Pluristem Therapeutics did give back some of those...
-
McNicoll, Lewis & Vlak Reiterates Alnylam Pharmaceuticals Buy, $15 PT
Monday, July 11, 2011 - 2:41pm | 85McNicoll, Lewis & Vlak reiterated its Alnylam Pharmaceuticals (NASDAQ: ALNY) Buy rating and $15 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "In our opinion, RNAi represents the next major therapeutic class; it has the potential to...